Home/Filings/4/0001209191-21-056530
4//SEC Filing

Jones Aranthan II 4

Accession 0001209191-21-056530

CIK 0001347178other

Filed

Sep 16, 8:00 PM ET

Accepted

Sep 17, 8:52 AM ET

Size

13.5 KB

Accession

0001209191-21-056530

Insider Transaction Report

Form 4
Period: 2021-09-15
Jones Aranthan II
Chief Corp. Affairs Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2021-09-15$11.32/sh+7,842$88,77198,804 total
  • Exercise/Conversion

    Common Stock

    2021-09-15$12.27/sh+4,277$52,47990,962 total
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    2021-09-154,27733,224 total
    Exercise: $12.27Exp: 2029-07-24Common Stock (4,277 underlying)
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    2021-09-157,84247,158 total
    Exercise: $11.32Exp: 2030-02-25Common Stock (7,842 underlying)
  • Sale

    Common Stock

    2021-09-15$16.49/sh16,824$277,39481,980 total
Footnotes (4)
  • [F1]A portion of the shares was sold to satisfy the exercise price and tax obligations relating to the acquisition of the shares in connection with the stock option exercise.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.40 to $16.605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
  • [F3]The option vested with respect to 25% of the underlying shares on July 25, 2020, with the remaining 75% of the shares vesting in 36 equal monthly installments beginning August 25, 2020, provided the Reporting Person remains continuously employed by the Issuer through each monthly vesting date.
  • [F4]The option vested with respect to 25% of the underlying shares on February 26, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person remains continuously employed by the Issuer through the applicable vesting date.

Issuer

Vanda Pharmaceuticals Inc.

CIK 0001347178

Entity typeother

Related Parties

1
  • filerCIK 0001785894

Filing Metadata

Form type
4
Filed
Sep 16, 8:00 PM ET
Accepted
Sep 17, 8:52 AM ET
Size
13.5 KB